News & Events

Recent Press Releases

Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab)…

GeneCentric to Present Data at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

GeneCentric to Present Data at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

GeneCentric to Present Data at the Association for Molecular Pathology 2015 Annual Meeting

GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the Association for Molecular Pathology (AMP) 2015 Annual Meeting being held November 5-7, 2015 at the Austin Convention Center in Austin, Texas.

Recent News

GeneCentric is 1 of 13 Companies Selected to Participate at this year’s CED Life Science Conference Showcase

GeneCentric is one of only 13 companies selected to participate at this year’s CED Life Science Conference Showcase. Dr. Myla Lai-Goldman, CEO of GeneCentric, will be presenting an overview of the company’s science and business model. The presentation will take place on Tuesday, March 3rd at 4:10pm at the Convention Center in Raleigh, North Carolina.

GeneCentic Presents Validation Study of it’s Lung Cancer Gene Expression Subtyping Panel

On November 15, 2014, at the annual Association of Molecular Pathology meeting in Maryland just outside Washington DC, GeneCentric presented a validation study of its Lung Cancer Gene Expression Subtyping Panel (LSP) using RT-qPCR of formalin fixed paraffin embedded samples. The LSP gene signature has been shown to be a robust method for classifying lung […]